NPC Submits Comments on Next Steps in the 21st Century Cures Initiative Read more about NPC Submits Comments on Next Steps in the 21st Century Cures Initiative
NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights Read more about NPC Comments Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds Read more about Development of New Indications for Small Molecule Drugs at Risk under Inflation Reduction Act’s Drug Price Negotiation Program, Study Finds
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications Read more about Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community Read more about Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community
How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation Read more about How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation
Oncology Drug Development: A Drug-Level Analysis of Subsequent Indications Read more about Oncology Drug Development: A Drug-Level Analysis of Subsequent Indications
Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry Read more about Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry